Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Dec 9;23(12):3254.
doi: 10.3390/molecules23123254.

Effects of Toona sinensis Leaf Extract and Its Chemical Constituents on Xanthine Oxidase Activity and Serum Uric Acid Levels in Potassium Oxonate-Induced Hyperuricemic Rats

Affiliations

Effects of Toona sinensis Leaf Extract and Its Chemical Constituents on Xanthine Oxidase Activity and Serum Uric Acid Levels in Potassium Oxonate-Induced Hyperuricemic Rats

Heung Joo Yuk et al. Molecules. .

Abstract

Toona sinensis leaf is used as a seasonal vegetable in Korea. A 70% ethanol extract of these leaves exhibited potent xanthine oxidase (XO) inhibition, with a 50% inhibitory concentration (IC50) of 78.4 µM. To investigate the compounds responsible for this effect, bioassay-guided purification led to the isolation of five constituents, identified as quercetin-3-O-rutinoside, quercetin-3-O-β-d-glucopyranoside, 1,2,3,4,6-penta-O-galloyl-β-d-glucopyranose (compound 3), quercetin-3-O-α-l-rhamnopyranoside, and kaempferol-3-O-α-l-rhamnopyranoside. Compound 3 showed the most potent inhibition of XO, with an IC50 of 2.8 µM. This was similar to that of allopurinol (IC50 = 2.3 µM), which is used clinically to treat hyperuricemia. Kinetic analyses found that compound 3 was a reversible noncompetitive XO inhibitor. In vivo, the T. sinensis leaf extract (300 mg/kg), or compound 3 (40 mg/kg), significantly decreased serum uric acid levels in rats with potassium oxonate-induced hyperuricemia. Furthermore, ultraperformance liquid chromatography-quadrupole time-of-flight mass spectrometry analysis identified a high level of compound 3 in the leaf extract. These findings suggest that T. sinensis leaves could be developed to produce nutraceutical preparations.

Keywords: Toona sinensis; hyperuricemia; ultraperformance liquid chromatography-quadrupole time-of-flight mass spectrometry; uric acid; xanthine oxidase.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Chemical structures of isolated compounds (15) from the leaves of T. sinensis.
Figure 2
Figure 2
(A) Inhibitory effects of compounds (15) on the activity of xanthine oxidase (XO) for the oxidation of xanthine to uric acid. (B) Catalytic activity of XO as a function of enzyme concentration at different concentrations of compound 3. (C) Lineweaver–Burk plots were constructed for the inhibition of XO by compound 3. The plot is expressed as 1/velocity versus 1/xanthine (S) with or without an inhibitor in the reaction solutions. (D) Dixon plots of XO inhibition by compound 3. The graphical symbols are substrate concentrations (50 μM, ●; 100 μM, ○; 200 μM, ▼).
Figure 3
Figure 3
Effects of 70% EtOH T. sinensis leaves (TSE) and compound 3 on serum uric acid levels in potassium oxonate (PO)-induced hyperuricemic rats. NC: normal control group; PO: potassium oxonate-induced hyperuricemia group; TSE-300: 300 mg/kg 70% EtOH TSE; AP-10: 10 mg/kg allopurinol. Data are expressed as the mean ± SEM (n = 6); ### p < 0.001 versus the NC group; * p < 0.05 and *** p < 0.005 versus the PO group.
Figure 4
Figure 4
Representative chromatograms of 70% EtOH extract from the leaves of T. sinensis: (A) Photodiode array (PDA) chromatogram and (B) total ion current-base peak intensity (TIC-BPI) chromatogram.

References

    1. Gibson T. Hyperuricemia, gout and the kidney. Curr. Opin. Rheumatol. 2012;24:127–131. doi: 10.1097/BOR.0b013e32834f049f. - DOI - PubMed
    1. Bitik B., Öztürk M.A. An old disease with new insights: Update on diagnosis and treatment of gout. Eur. J. Rheumatol. 2014;1:72–77. doi: 10.5152/eurjrheumatol.2014.021. - DOI - PMC - PubMed
    1. Martillo M.A., Nazzal L., Crittenden D.B. The crystallization of monosodium urate. Curr. Rheumatol. Rep. 2014;16:400. doi: 10.1007/s11926-013-0400-9. - DOI - PMC - PubMed
    1. Redon P., Maloberti A., Facchetti R., Redon J., Lurbe E., Bombelli M., Mancia G., Grassi G. Gender-related differences in serum uric acid in treated hypertensive patients from central and east European countries: findings from the blood pressure control rate and cardiovascular risk profile study. J. Hypertens. 2018 doi: 10.1097/HJH.0000000000001908. - DOI - PubMed
    1. Maloberti A., Maggioni S., Occhi L., Triglione N., Panzeri F., Nava S., Signorini S., Falbo R., Casati M., Grassi G., Giannattasio C. Sex-related relationships between uric acid and target organ damage in hypertension. J. Clin. Hypertens. (Greenwich). 2018;20:193–200. doi: 10.1111/jch.13136. - DOI - PMC - PubMed

LinkOut - more resources